Published March 4, 2013 | Version v1
Journal article

Risk of second cancer from scattered radiation of intensity-modulated radiotherapies with lung cancer

  • 1. Department of Radiation Oncology, Kyung Hee University Hospital at Gangdong, Seoul (Korea, Republic of)
  • 2. Proton Therapy Center, National Cancer Center, Ilsan (Korea, Republic of)
  • 3. Department of Radiological Science, College of Health Science, Korea University, Jeongneung 3-dong, Seongbuk-gu, Seoul (Korea, Republic of)
  • 4. Department of Radiation Oncology, Kyung Hee University Medical Center, Seoul (Korea, Republic of)
  • 5. Department of medical Physics, Asan Medical Center, College of Medicine, University of Ulsan, Seoul (Korea, Republic of)
  • 6. Proton Therapy Center, McLaren Cancer Institute, Flint (United States)

Description

To compare the risk of secondary cancer from scattered and leakage doses following intensity-modulated radiotherapy (IMRT), volumetric arc therapy (VMAT) and tomotherapy (TOMO) in patients with lung cancer. IMRT, VMAT and TOMO were planned for five lung cancer patients. Organ equivalent doses (OEDs) are estimated from the measured corresponding secondary doses during irradiation at various points 20 to 80 cm from the iso-center by using radio-photoluminescence glass dosimeter (RPLGD). The secondary dose per Gy from IMRT, VMAT and TOMO for lung cancer, measured 20 to 80 cm from the iso-center, are 0.02~2.03, 0.03~1.35 and 0.04~0.46 cGy, respectively. The mean values of relative OED of secondary dose of VMAT and TOMO, which is normalized by IMRT, ranged between 88.63% and 41.59% revealing 88.63% and 41.59% for thyroid, 82.33% and 41.85% for pancreas, 77.97% and 49.41% for bowel, 73.42% and 72.55% for rectum, 74.16% and 81.51% for prostate. The secondary dose and OED from TOMO became similar to those from IMRT and VMAT as the distance from the field edge increased. OED based estimation suggests that the secondary cancer risk from TOMO is less than or comparable to the risks from conventional IMRT and VMAT

Availability note (English)

Available from http://dx.doi.org/10.1186/1748-717X-8-47; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599921

Additional details

Publishing Information

Journal Title
Radiation Oncology (Online)
Journal Volume
8
Journal Page Range
p. 47
ISSN
1748-717X

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47062076
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
COMPUTERIZED TOMOGRAPHY; CT-GUIDED RADIOTHERAPY; DOSE EQUIVALENTS; GY RANGE; HAZARDS; LUNGS; NEOPLASMS
Descriptors DEC
ABSORBED DOSE RANGE; BODY; DIAGNOSTIC TECHNIQUES; DISEASES; MEDICINE; NUCLEAR MEDICINE; ORGANS; RADIATION DOSE RANGES; RADIOLOGY; RADIOTHERAPY; RESPIRATORY SYSTEM; THERAPY; TOMOGRAPHY

Optional Information

Copyright
Copyright (c)2013 Kim et al
Notes
PMCID: PMC3599921; PUBLISHER-ID: 1748-717X-8-47; PMID: 23452670; OAI: oai:pubmedcentral.nih.gov:3599921; licensee BioMed Central Ltd.